| answer text |
<p>The Department meets with the National Institute of Health and Care Excellence
(NICE) regularly to discuss a range of issues, including access to medicines. The
NICE has formally started its appraisal of AZD-3152, also known as sipavibart and
referred to as Evusheld 2, ahead of the Medicines and Healthcare products Regulatory
Agency’s (MHRA) decision on whether it should be given a United Kingdom marketing
authorisation, and expects to invite stakeholder submissions in April 2024. Timelines
for both the NICE’s guidance and licensing depend on data from the SUPERNOVA trial
being available. AstraZeneca intends to submit clinical data to the NICE and the MHRA
at the same time, with the aim that both organisations are able to reach decisions
as close together as possible. If AZD-3152 is recommended as clinically and cost effective
by the NICE, the National Health Service in England will be under a statutory requirement
to fund AZD-3152 for eligible patients, in line with the NICE’s recommendations.</p>
|
|
